P2Y12 Inhibitors in STEMI Patients - One Size Does Not Fit All.
作者信息
Patel Rajiv C, Jones Jeffrey E, Stouffer George A
机构信息
Division of Cardiology and the McAllister Heart Institute, University of North Carolina, Chapel Hill, NC, USA.
出版信息
Cardiovasc Drugs Ther. 2024 Feb;38(1):5-7. doi: 10.1007/s10557-023-07497-2. Epub 2023 Aug 2.
Abstract
摘要
相似文献
1
P2Y12 Inhibitors in STEMI Patients - One Size Does Not Fit All.ST段抬高型心肌梗死患者中的P2Y12抑制剂——并非一概而论
Cardiovasc Drugs Ther. 2024 Feb;38(1):5-7. doi: 10.1007/s10557-023-07497-2. Epub 2023 Aug 2.
2
Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.行直接经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者的最佳 P2Y12 抑制剂：网状荟萃分析。
JACC Cardiovasc Interv. 2016 May 23;9(10):1036-46. doi: 10.1016/j.jcin.2016.02.013.
3
Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.美国ST段抬高型心肌梗死患者中P2Y12抑制剂的医生及医院使用情况：一项来自国家心血管数据注册中心“研究到实践”倡议的研究
Circ Cardiovasc Qual Outcomes. 2020 Mar;13(3):e006275. doi: 10.1161/CIRCOUTCOMES.119.006275. Epub 2020 Mar 11.
4
Translation of experimental cardioprotective capability of P2Y inhibitors into clinical outcome in patients with ST-elevation myocardial infarction.将 P2Y 抑制剂的实验性心脏保护能力转化为 ST 段抬高型心肌梗死患者的临床结局。
Basic Res Cardiol. 2021 May 26;116(1):36. doi: 10.1007/s00395-021-00870-y.
5
Efficacy of prasugrel administration immediately after percutaneous coronary intervention in ST-elevation myocardial infarction.ST段抬高型心肌梗死患者经皮冠状动脉介入治疗后立即给予普拉格雷的疗效。
Thromb Haemost. 2017 Jan 5;117(1):99-104. doi: 10.1160/TH16-07-0569. Epub 2016 Oct 13.
6
Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based study.接受经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者中 P2Y12 抑制剂的有效性和安全性：一项基于全国登记的研究。
Eur Heart J Acute Cardiovasc Care. 2022 Sep 29;11(9):697-705. doi: 10.1093/ehjacc/zuac095.
7
Infarct Size Following Treatment With Second- Versus Third-Generation P2Y12 Antagonists in Patients With Multivessel Coronary Disease at ST-Segment Elevation Myocardial Infarction in the CvLPRIT Study.在CvLPRIT研究中，接受第二代与第三代P2Y12拮抗剂治疗的多支冠状动脉疾病伴ST段抬高型心肌梗死患者的梗死面积。
J Am Heart Assoc. 2016 May 31;5(6):e003403. doi: 10.1161/JAHA.116.003403.
8
Features of antiplatelet therapy with P2Y12 receptor inhibitors in patients with myocardial infarction according to the Russian Register of Acute Myocardial Infarction REGION-MI.根据俄罗斯急性心肌梗死登记处REGION-MI的数据，心肌梗死患者使用P2Y12受体抑制剂进行抗血小板治疗的特点。
Kardiologiia. 2022 Sep 30;62(9):44-53. doi: 10.18087/cardio.2022.9.n2278.
9
Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.在直接经皮冠状动脉介入治疗中，患者预先使用氯吡格雷后给予普拉格雷负荷剂量的安全性：一项非随机观察性研究的结果。
JACC Cardiovasc Interv. 2015 Jul;8(8):1064-1074. doi: 10.1016/j.jcin.2015.03.023.
10
Comparison of Heart Rates in Patients Initiated on Ticagrelor Versus Other P2Y12 Inhibitors After an Inferior ST Elevation Myocardial Infarction (STEMI).下壁ST段抬高型心肌梗死（STEMI）后起始使用替格瑞洛与其他P2Y12抑制剂的患者心率比较。
Ann Pharmacother. 2025 Feb;59(2):142-147. doi: 10.1177/10600280241255111. Epub 2024 May 30.
本文引用的文献
1
Dual Antiplatelet Therapy with 3 Generation P2Y Inhibitors in STEMI Patients: Impact of Body Mass Index on Loading Dose-Response.替格瑞洛或普拉格雷用于 ST 段抬高型心肌梗死患者的疗效与安全性比较
Cardiovasc Drugs Ther. 2023 Aug;37(4):695-703. doi: 10.1007/s10557-022-07322-2. Epub 2022 Feb 17.
2
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.2020年欧洲心脏病学会非持续性ST段抬高型急性冠状动脉综合征患者管理指南
Eur Heart J. 2021 Apr 7;42(14):1289-1367. doi: 10.1093/eurheartj/ehaa575.
3
Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention.CYP2C19 基因分型指导急性冠状动脉综合征或经皮冠状动脉介入治疗患者抗血小板治疗的临床实用性。
Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):647-652. doi: 10.1161/ATVBAHA.118.311963.
4
Do We Need Potent Intravenous Antiplatelet Inhibition at the Time of Reperfusion During ST-Segment Elevation Myocardial Infarction?在 ST 段抬高型心肌梗死再灌注时是否需要强效静脉抗血小板抑制？
J Cardiovasc Pharmacol Ther. 2019 May;24(3):215-224. doi: 10.1177/1074248418812167. Epub 2018 Dec 18.
5
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.多中心研究：经皮冠状动脉介入治疗后实施 CYP2C19 基因指导的抗血小板治疗的结果。
JACC Cardiovasc Interv. 2018 Jan 22;11(2):181-191. doi: 10.1016/j.jcin.2017.07.022. Epub 2017 Nov 1.
6
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).2017年欧洲心脏病学会（ESC）ST段抬高型急性心肌梗死患者管理指南：欧洲心脏病学会（ESC）ST段抬高型急性心肌梗死患者管理工作组
Eur Heart J. 2018 Jan 7;39(2):119-177. doi: 10.1093/eurheartj/ehx393.
7
Efficacy of prasugrel administration immediately after percutaneous coronary intervention in ST-elevation myocardial infarction.ST段抬高型心肌梗死患者经皮冠状动脉介入治疗后立即给予普拉格雷的疗效。
Thromb Haemost. 2017 Jan 5;117(1):99-104. doi: 10.1160/TH16-07-0569. Epub 2016 Oct 13.
8
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2016美国心脏病学会/美国心脏协会关于冠状动脉疾病患者双联抗血小板治疗持续时间的指南聚焦更新：美国心脏病学会/美国心脏协会临床实践指南工作组报告
J Am Coll Cardiol. 2016 Sep 6;68(10):1082-115. doi: 10.1016/j.jacc.2016.03.513. Epub 2016 Mar 29.
9
Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者应用碾碎普拉格雷片：CRUSH 研究。
J Am Coll Cardiol. 2016 May 3;67(17):1994-2004. doi: 10.1016/j.jacc.2016.02.045. Epub 2016 Mar 21.
10
Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study.替格瑞洛碾碎片用于ST段抬高型心肌梗死患者：莫吉托研究
J Am Coll Cardiol. 2015 Feb 10;65(5):511-2. doi: 10.1016/j.jacc.2014.08.056.
Zotero 插件